Cardona S, Tsegka K, Pasquel FJ, et al. - Researchers performed this double‐blinded, placebo‐controlled trial to determine if among patients with type 2 diabetes undergoing coronary artery bypass graft (CABG) surgery, the severity of perioperative hyperglycaemia could be prevented and reduced by treatment with sitagliptin, initiated prior to surgery and continued during the hospital stay. Adults with type 2 diabetes were randomized to receive sitagliptin or matching placebo initiated 1 day before surgery and continued during the hospital stay. According to findings, perioperative hyperglycaemia or complications post-CABG were not prevented by sitagliptin when administered prior to surgery and during the hospital stay. Sitagliptin treatment was found to be related to lower mean daily insulin needs following transition to regular wards.